Source comparison
BPC-157 Nerve Repair — Research Protocol Comparison
Dosing Range 10 mcg/kg – 10 mg/kg IP or local injection 10 mcg/kg – 1 mg/kg IP, initiated within 30 min post-injury 10 mcg/kg daily, 14–21 day protocols Human equivalent doses (HED) calculated via BSA conversion would be 1.6 mcg/kg – 1.6 mg/kg, though cross-sp
This comparison does not assign a generated winner or score.
- Dosing Range
- 10 mcg/kg – 10 mg/kg IP or local injection
- 10 mcg/kg – 1 mg/kg IP, initiated within 30 min post-injury
- 10 mcg/kg daily, 14–21 day protocols
- Human equivalent doses (HED) calculated via BSA conversion would be 1.6 mcg/kg – 1.6 mg/kg, though cross-species pharmacokinetics remain unvalidated
- Administration Route
- Intraperitoneal (systemic) or direct perineural injection at injury site
- Intraperitoneal; intrathecal routes show enhanced local concentration but increase procedural risk
- Intraperitoneal; oral administration shows poor bioavailability in GI models
- Local administration achieves 3–5× higher tissue concentration at injury sites but requires precise anatomical targeting
- Treatment Duration
- 7–28 days post-injury; single-dose studies show transient effects only
- 14–42 days; longer protocols show incremental benefit beyond day 28
- 14–21 days; cessation before day 14 results in symptom rebound within 72 hours
- Optimal duration appears injury-severity dependent; severe injuries require sustained administration through peak regenerative phase
- Functional Recovery Metrics
- Gait analysis (CatWalk), nerve conduction velocity, compound muscle action potential amplitude
- BBB locomotor scale, electrophysiological mapping, histological axon counts
- Mechanical allodynia threshold (von Frey testing), thermal hyperalgesia latency
- Functional tests correlate moderately with histological findings (r=0.65–0.75); combined endpoints provide clearer efficacy picture
- Observed Effect Size
- 40–60% faster return to baseline function vs controls; 35–45% increase in GAP-43 expression
- 20–25% improvement in locomotor scores; modest axonal sparing (15–20% increase in preserved fibers)
- 35–40% reduction in pain behaviors; effect persists 7–10 days post-treatment
- Effect magnitude scales inversely with injury severity. Complete transection shows minimal benefit vs partial lesions
- Professional Assessment
- Most robust evidence base; mechanism well-characterized; reproducible across labs and injury models
- Promising but modest effects; CNS barriers (glial scar, myelin inhibitors) limit regeneration regardless of compound
- Pain reduction may reflect anti-inflammatory effects rather than true nerve repair; supportive but not primary indication
- Peripheral nerve applications show clearest translational potential; CNS applications require combination approaches targeting multiple regeneration barriers simultaneously